BIO vs ELDN · rev $2.58B vs $209.6M cap
BIO (BIO) versus Eledon Pharmaceuticals Inc (ELDN) — a side-by-side from cached financials, not a winner call.
BIO (BIO) common stock.
Eledon Pharmaceuticals Inc (ELDN) is a biotechnology company listed on US.
Latest reported BIO revenue for 2025-12-31 was $2.58B. Net income was $759.9M. Revenue was up 0.7% from 2024-12-31 to 2025-12-31. BIO currently screens at market cap $0.
ELDN does not have a complete income-statement cache yet.
BIO currently screens at market cap $0. ELDN currently screens at market cap $209.6M.
Not investment advice. Open the BIO and ELDN stock pages for the full models.
Not investment advice.